Buck E. Rogers
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (29)
Supplementary Figure 9. A. HPLC-SEC analysis of L111 and L111-DFO on an Agilent 1200 series HPLC system using a Zorbax GF-250 9.4 mm ID x 25 cm column (Agilent). DFO conjugation did not change the retention time of the antibody, and no aggregation was observed. B. iTLC showing the radiochemical purity of the radiolabeled L111 antibody. C. Radio-HPLC confirming the radiolabeling of the L111 antibody with [89Zr]Zr.
Year:
2024
Supplementary Figure 7. Biophysical characterization of the purified L111 antibody. A. Analysis of purified L111 antibody integrity by non-reduced (top) and reduced (bottom) capillary electrophoresis-SDS (CE-SDS) on a Perkin Elmer LabChip GXII Touch HT. The table shows the size and migration times of the non-reduced and reduced antibody samples. B. Size-exclusion chromatography high-performance liquid chromatography (SEC-HPLC) analysis of the purified L111 antibody. The table shows the percentage of monomers and high molecular weight species (HMWS). C. Cation-exchange chromatography of the purified L111 antibody. D. Deconvoluted mass spectrometry spectra of the purified L111 antibody. E and F. Analysis of Fc N-Glycan profiles and major glycans distribution by Hydrophilic interaction liquid chromatography (HILIC)-in combination with fluorescence detection (FLD). F. Table shows the percentage of each N-Glycan in the L111 antibody.
Year:
2024
Supplementary Figure 4. SDS-PAGE of eight unique purified human anti-TIP1 full-length IgGs under non-reducing (A) and reducing conditions (B). A. Intact full-length IgGs are observed above 150 kDa. B. In the reducing condition, heavy chains and light chains are observed at 50 kDa and 25 kDa, respectively.
Year:
2024
Purpose: Tax-interacting protein 1 (TIP1) is a cancer-specific radiation-inducible cell surface antigen that plays a role in cancer progression and resistance to therapy. This study aimed to develop a novel anti-TIP1 human antibody for noninvasive PET imaging in patients with cancer. Experimental Design: A phage-displayed single-chain variable fragment (scFv) library was created from healthy donors’ blood. High-affinity anti-TIP1 scFvs were selected from the library and engineered to human IgG1. Purified Abs were characterized by size exclusion chromatography high-performance liquid chromatography (SEC-HPLC), native mass spectrometry (native MS), ELISA, BIAcore, and flow cytometry. The labeling of positron emitter [ 89 Zr]Zr to the lead Ab, L111, was optimized using deferoxamine (DFO) chelator. The stability of [ 89 Zr]Zr-DFO-L111 was assessed in human serum. Small animal PET studies were performed in lung cancer tumor models (A549 and H460). Results: We obtained 95% pure L111 by SEC-HPLC. Native MS confirmed the intact mass and glycosylation pattern of L111. Conjugation of three molar equivalents of DFO led to the optimal DFO-to-L111 ratio of 1.05. Radiochemical purity of 99.9% and specific activity of 0.37 MBq/μg was obtained for [ 89 Zr]Zr-DFO-L111. [ 89 Zr]Zr-DFO-L111 was stable in human serum over 7 days. The immunoreactive fraction in cell surface binding studies was 96%. In PET, preinjection with 4 mg/kg cold L111 before [ 89 Zr]Zr-DFO-L111 (7.4 MBq; 20 μg) significantly ( P Conclusions: L111 Ab targets lung cancer cells in vitro and in vivo . [ 89 Zr]Zr-DFO-L111 is a human antibody that will be evaluated in the first in-human study of safety and PET imaging.
Year:
2024
Purpose: Tax-interacting protein 1 (TIP1) is a cancer-specific radiation-inducible cell surface antigen that plays a role in cancer progression and resistance to therapy. This study aimed to develop a novel anti-TIP1 human antibody for noninvasive PET imaging in patients with cancer. Experimental Design: A phage-displayed single-chain variable fragment (scFv) library was created from healthy donors’ blood. High-affinity anti-TIP1 scFvs were selected from the library and engineered to human IgG1. Purified Abs were characterized by size exclusion chromatography high-performance liquid chromatography (SEC-HPLC), native mass spectrometry (native MS), ELISA, BIAcore, and flow cytometry. The labeling of positron emitter [ 89 Zr]Zr to the lead Ab, L111, was optimized using deferoxamine (DFO) chelator. The stability of [ 89 Zr]Zr-DFO-L111 was assessed in human serum. Small animal PET studies were performed in lung cancer tumor models (A549 and H460). Results: We obtained 95% pure L111 by SEC-HPLC. Native MS confirmed the intact mass and glycosylation pattern of L111. Conjugation of three molar equivalents of DFO led to the optimal DFO-to-L111 ratio of 1.05. Radiochemical purity of 99.9% and specific activity of 0.37 MBq/μg was obtained for [ 89 Zr]Zr-DFO-L111. [ 89 Zr]Zr-DFO-L111 was stable in human serum over 7 days. The immunoreactive fraction in cell surface binding studies was 96%. In PET, preinjection with 4 mg/kg cold L111 before [ 89 Zr]Zr-DFO-L111 (7.4 MBq; 20 μg) significantly ( P Conclusions: L111 Ab targets lung cancer cells in vitro and in vivo . [ 89 Zr]Zr-DFO-L111 is a human antibody that will be evaluated in the first in-human study of safety and PET imaging.
Year:
2024
Supplementary Figure 9. A. HPLC-SEC analysis of L111 and L111-DFO on an Agilent 1200 series HPLC system using a Zorbax GF-250 9.4 mm ID x 25 cm column (Agilent). DFO conjugation did not change the retention time of the antibody, and no aggregation was observed. B. iTLC showing the radiochemical purity of the radiolabeled L111 antibody. C. Radio-HPLC confirming the radiolabeling of the L111 antibody with [89Zr]Zr.
Year:
2024
Supplementary Figure 6. Flow cytometry evaluation of the purified anti-TIP1 antibodies on H460 (A) and A549 (B) cells. The percentage of anti-TIP1+ vs. antibody concentration was plotted in GraphPad Prism software using One Site-specific binding model. The table below represents the Kd values. C. Immunohistochemistry shows intense TIP1 staining in the human patient-derived xenograft tissue.
Year:
2024
Supplementary Figure 2. A. Colony PCR showing the completeness of the WashU II library. B. Western blots for the WashU II phages at different dilutions were developed with an anti-pIII antibody showing the fused scFv with the pIII coat protein of the M13 phage. C. Western blots for the WashU II phages at different dilutions were developed with an anti-Flag antibody showing the full-length scFv on the M13 phage.
Year:
2024
Supplementary Figure 12. In vitro characterization of [89Zr]Zr-DFO-L111. A. SDS-PAGE under non-reducing and reducing conditions for the [89Zr]Zr-DFO-L111 developed by autoradiography. Four two-fold dilutions were loaded on the SDS-PAGE gel and developed by autoradiography. B. ELISA assay showing binding affinity of the [89Zr]Zr-DFO-L111 to recombinant TIP1 protein.
Year:
2024
Supplementary Figure 11. Specific uptake of the [89Zr]Zr-DFO-L111 in tumors in vivo. Bar graph showing the uptake of the [89Zr]Zr-DFO-Isotype or [89Zr]Zr-DFO-L111 at days 2 and 5 in nude mice bearing A549 tumors in the hindlimb (n=4). Tumors were irradiated with three doses of 3Gy over 24h, followed by injection with radiolabeled antibodies. Cold anti-TIP1 Ab was injected before injecting the radiolabeled for the blocking study. Bar graphs represent %ID/gm. *P
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2022
Collaborators (6)
Michael Nickels
Associate Professor
University of Washington Medical Center
Dennis Hallahan
Professor-Joint Appointment
Washington University in St. Louis
Yongjian Liu
Washington University in St. Louis
Shunqiang Li
Associate Professor
Washington University in St. Louis
Abhay Singh
Assistant Professor
Washington University in St. Louis
Vaishali Kapoor
Associate Professor
Washington University in Saint Louis School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.